A new directive from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) has formally reclassified obesity as a chronic inflammatory disease, moving beyond its traditional status as a risk factor. The guideline signals a structural shift in clinical practice across Latin America’s largest health system, where diabetes prevalence has risen 135% since 2006 and now generates direct costs exceeding 42 billion reais annually. At the same time, a study of 80,000 beneficiaries by the health operator Alice found that diabetics managed through integrated primary care had a hospitalisation rate of 37 per 100,000 members—roughly one-third of the OECD average—and that 60% achieved glycaemic control.

The model relies on continuous coordination by family doctors, nurse teams, and digital tools that aggregate real-time clinical data, enabling early medication adjustments and systematic monitoring of haemoglobin A1c. Across the monitored population, 83% underwent the test within a year, and only 13% of patients progressed to severe disease. Clinicians in São Paulo attribute the 6% 30-day readmission rate—less than half the floor estimated by the American Diabetes Association—to proactive intervention before metabolic decompensation occurs. Analysts in Brazil note that rebranding obesity as a systemic, neuroendocrine condition rather than a consequence of individual behaviour is already prompting operators to adopt structured, long-term protocols that target inflammation and hormonal imbalances, not merely caloric restriction.

Evidence supporting this approach was reinforced at the American Diabetes Association’s Scientific Sessions, where sub-analyses of the SELECT trial showed that semaglutide 2.4 mg, already approved for weight management, reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease. Additional benefits were observed across hypertension, sleep apnoea, asthma, and markers of hepatic health, consistent with the drug’s effect on systemic inflammation. Endocrinologists in Buenos Aires highlight that the medication’s impact on quality of life—restoring mobility, reducing breathlessness, enabling everyday activities—reflects the multidimensional damage that excess adiposity inflicts on organs and tissues.

The convergence of a revised disease framework, real-world care coordination data, and pharmacotherapy that addresses underlying inflammatory pathways is reshaping clinical conversations well beyond Brazil. Health authorities in the region note that without redirection, diabetes cases in Latin America could rise a further 45% by 2050. The next practical milestone will be the adoption of Abeso’s guidelines by public and private payers, while surgical options such as robotic-assisted metabolic procedures—which have grown more than 400% in Brazil—are likely to be positioned as tools within this broader, integrated strategy rather than standalone interventions.